The consequences of combined oral contraception for insulin sensitivity were mainly associated with the progestin component; therefore, the antiandrogenic properties of cyproterone acetate may be associated with decreases in insulin resistance and reductions in circulating androgen levels among women with PCOS, thereby producing the FBG levels observed.87 However, the clinical importance of the impact of different progestins was likely to be minimal, and the use of any combined oral contraceptive agent was unlikely to be associated with diabetes among women with PCOS.88 This evidence concerns the gene INS and polycystic ovary syndrome.